The report provides industry landscape, competitive landscape and industry trends data on the cardiac markers industry . The report provides comprehensive data on the major industry developments affecting the industry, and key analytical content on the industry dynamics. The report also reviews the competitive landscape and technology offerings.


Scope of the Research

- Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
- Annualized industry revenues data from 2003 to 2010, projection forward for 7 years to 2017. Firms shares data for 2009.
- Qualitative analysis of key industry trends, industry drivers, and restraints by each category within cardiac markers industry .
- The report also covers data on the leading industry players, the competitive landscape, and the leading new product development and technologies.
- Key Companies covered include F. Hoffmann-La Roche Ltd, Abbott Laboratories, Siemens Healthcare, Alere and Beckman Coulter.

Why Should You Get This Report?

- Develop business strategies by understanding the trends and developments that are driving the cardiac markers industry globally.
- Design and develop your product development, industry ing and sales strategies.
- Develop successful market-entry strategies .
- Identify key players best positioned to take advantage of the emerging industry opportunities.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- What’s the next big thing in the cardiac markers industry landscape? – Identify, understand and decide.
- Make more informed business decisions from the insightful and in-depth analysis of the global cardiac markers industry and the factors shaping it.

Table Of Contents

1 Table of contents

I Table of contents 3
I. 1 List of Data tables 5
I. 2 List of Charts 6

II Introduction 7
II. 1 GlobalData Report Guidance 7

III Cardiovascualr Disease Data 8
III. 1 Pathophysiology 8
III. 2 Disease Burden 9
III. 3 Diagnosis 10

IV Cardiac March kers: March ket Characterization 11
IV. 1 Cardiac March kers March ket, Global, Sales (USD Million), Historical data, from 2003 to 2010 11
IV. 2 Cardiac March kers March ket, Global, Sales (USD Million), Forecasted data, from 2010 to 2017 12
IV. 3 Cardiac March kers, Key Trends 13
IV. 3.1 Lab-on--a Chip Cardiac Sensor System 13
IV. 3.2 Use of Predictive March kers for Personalized Treatment 13
IV. 3.3 High-Sensitivity CRP (hs-CRP) 14
IV. 3.4 Heart-Type Fatty Acid Binding Protein (H-FABP) 14
IV. 3.5 Cardiac Biomarker Soluble ST2 (sST2) Exhibits Significant Clinical Value 15
IV. 3.6 Myeloperoxidase (MPO) 15
IV. 3.7 Brain Natriuretic Peptide (BNP) 15
IV. 4 Cardiac March kers, March ket Dynamics 16
IV. 4.1 Cardiac March kers, March ket Drivers 16
IV. 4.2 Cardiac March kers March ket Restraints 18
5 World Cardiac March kers March ket, by Country, Sales (USD Million), from 2003 to 2017 19
V. 1 Cardiac March kers March ket, the US, Sales (USD Million), Historical data, 2003 - 2010 19
V. 2 Cardiac March kers March ket, the US, Sales (USD Million), Forecasted data, 2010 - 2017 20
V. 3 Cardiac March kers March ket, Canada, Sales (USD Million), Historical data, 2003 - 2010 21
V. 4 Cardiac March kers March ket, Canada, Sales (USD Million), Forecasted data, 2010 - 2017 22
V. 5 Cardiac March kers March ket, the UK, Sales (USD Million), Historical data, 2003 - 2010 23
V. 6 Cardiac March kers March ket, the UK, Sales (USD Million), Forecasted data, 2010 - 2017 24
V. 7 Cardiac March kers March ket, Germany, Sales (USD Million), Historical data, 2003 - 2010 25
V. 8 Cardiac March kers March ket, Germany, Sales (USD Million), Forecasted data, 2010 - 2017 26
V. 9 Cardiac March kers March ket, France, Sales (USD Million), Historical data, 2003 - 2010 27
V. 10 Cardiac March kers March ket, France, Sales (USD Million), Forecasted data, 2010 - 2017 28
V. 11 Cardiac March kers March ket, Italy, Sales (USD Million), Historical data, 2003 - 2010 29
V. 12 Cardiac March kers March ket, Italy, Sales (USD Million), Forecasted data, 2010 - 2017 30
V. 13 Cardiac March kers March ket, Spain, Sales (USD Million), Historical data, 2003 - 2010 31
V. 14 Cardiac March kers March ket, Spain, Sales (USD Million), Forecasted data, 2010 - 2017 32
V. 15 Cardiac March kers March ket, Japan, Sales (USD Million), Historical data, 2003 - 2010 33
V. 16 Cardiac March kers March ket, Japan, Sales (USD Million), Forecasted data, 2010 - 2017 34
V. 17 Cardiac March kers March ket, China, Sales (USD Million), Historical data, 2003 - 2010 35
V. 18 Cardiac March kers March ket, China, Sales (USD Million), Forecasted data, 2010 - 2017 36
V. 19 Cardiac March kers March ket, India, Sales (USD Million), Historical data, 2003 - 2010 37
V. 20 Cardiac March kers March ket, India, Sales (USD Million), Forecasted data, 2010 - 2017 38
V. 21 Cardiac March kers March ket, Australia, Sales (USD Million), Historical data, 2003 - 2010 39
V. 22 Cardiac March kers March ket, Australia, Sales (USD Million), Forecasted data, 2010 - 2017 40
V. 23 Cardiac March kers March ket, Brazil, Sales (USD Million), Historical data, from 2003 to 2010 41
V. 24 Cardiac March kers March ket, Brazil, Sales (USD Million), Forecasted data, 2010 - 2017 42

VI Cardiac March kers March ket: Strategic Competitive Assessment 43
VI. 1 Cardiac March kers March ket, Global, Market Shares (%), 2010 43
VI. 2 Cardiac March kers March ket, Competitive Analysis 44
VI. 2.1 Threat of Rivalry 44
VI. 2.2 Threat of New Entrants 45
VI. 2.3 Buyer Power 45
VI. 2.4 Threat of Substitute 45
VI. 2.5 Supplier Power 45
VI. 3 Cardiac March kers: Key March ket Participants 46
VI. 3.1 F. Hoffmann-La Roche Ltd. 46
VI. 3.2 Abbott Laboratories 48
VI. 3.3 Siemens Healthcare 50
VI. 3.4 Alere 53
VI. 3.5 Beckman Coulter, Inc. 55

VII Key March keted Cardiac March kers 58
VII. 1 TROP T Sensitive Rapid Assay 58
VII. 1.1 Product Description 58
VII. 1.2 Features and Benefits 58
VII. 2 Cobas c 111 Analyzer 58
VII. 2.1 Product Description 58
VII. 2.2 Features and Benefits 58
VII. 3 I-STAT System 59
VII. 3.1 Product Description 59
VII. 3.2 Features and Benefits 59
VII. 4 Stratus CS Analyzer 59
VII. 4.1 Product Description 59
VII. 4.2 Features and Benefits 59
VII. 5 TriageBNP 60
VII. 5.1 Product Description 60
VII. 5.2 Features and Benefits 60

VIII Cardiac March kers March ket: Strategic Pipeline Assessment 61
VIII. 1 Device Pipeline Products Summary 61
VIII. 2 Profiles of Promising Products Under Clinical Development 65
VIII. 2.1 VASCLIR 65
VIII. 2.2 ARCHITECT MPO ASSAY 66
VIII. 2.3 CADPrint 67
VIII. 2.4 Presage ST2 Assay 68
VIII. 2.5 Verigene Cardiac Troponin I Assay 69
VIII. 2.6 Lab-on-a -Film Cardiac Sensor System 71

IX Cardiac March ker March ket: Strategic Deals Analysis 72
IX. 1 Key Acquisitions 72
IX. 1.1 Danaher to Acquire Beckman Coulter 72
IX. 1.2 bioMerieux Completed the Acquisition of Meikang Biotech (Shanghai) 72
IX. 1.3 Inverness Medical Innovations Acquired 78.13% Stake in Standard Diagnostics 73
IX. 1.4 VaxGen Completed Acquisition of diaDexus 73
IX. 1.5 Siemens Medical Solutions Acquired Dade Behring 73
IX. 2 Key Partner agreements 74
IX. 2.1 BG Medicine Enters Into an Agreement with Siemens Healthcare Diagnostics 74
IX. 2.2 Axis-Shield Signs Option Agreement with Bio-Rad Laboratories 74

X Appendix 75
X. 1 Definitions 76
X. 1.1 Cardiac March kers 76
X. 2 Acronyms 76
X. 3 Sources 77
X. 4 Research Methodology 77
X. 5 Secondary Research 77
X. 6 Primary Research 78
X. 7 Models 78
X. 8 Forecasted data s 78
X. 9 Expert Panels 79
X. 10 GlobalData Consulting 79
X. 11 Contact Us 79
X. 12 Disclaimer 79

1.1 List of Data tables
Data table 1: Cardiac March kers March ket, Global, Sales (USD Million), from 2003 to 2010 11
Data table 2: Cardiac March kers March ket, Global, Sales (USD Million), 2010- 2017 12
Data table 3: Pipeline hs-CRP Cardiac March kers 14
Data table 4: Pipeline MPO Cardiac March kers 15
Data table 5: Commercial POC Testing for Cardiac March kers 17
Data table 6: Cardiac March kers March ket, the US, Sales (USD Million), from 2003 to 2010 19
Data table 7: Cardiac March kers March ket, the US, Sales (USD Million), from 2010 to 2017 20
Data table 8: Cardiac March kers March ket, Canada, Sales (USD Million), from 2003 to 2010 21
Data table 9: Cardiac March kers March ket, Canada, Sales (USD Million), from 2010 to 2017 22
Data table 10: Cardiac March kers March ket, the UK, Sales (USD Million), from 2003 to 2010 23
Data table 11: Cardiac March kers March ket, the UK, Sales (USD Million), from 2010 to 2017 24
Data table 12: Cardiac March kers March ket, Germany, Sales (USD Million), from 2003 to 2010 25
Data table 13: Cardiac March kers March ket, Germany, Sales (USD Million), from 2010 to 2017 26
Data table 14: Cardiac March kers March ket, France, Sales (USD Million), from 2003 to 2010 27
Data table 15: Cardiac March kers March ket, France, Sales (USD Million), from 2010 to 2017 28
Data table 16: Cardiac March kers March ket, Italy, Sales (USD Million), from 2003 to 2010 29
Data table 17: Cardiac March kers March ket, Italy, Sales (USD Million), from 2010 to 2017 30
Data table 18: Cardiac March kers March ket, Spain, Sales (USD Million), from 2003 to 2010 31
Data table 19: Cardiac March kers March ket, Spain, Sales (USD Million), from 2010 to 2017 32
Data table 20: Cardiac March kers March ket, Japan, Sales (USD Million), from 2003 to 2010 33
Data table 21: Cardiac March kers March ket, Japan, Sales (USD Million), from 2010 to 2017 34
Data table 22: Cardiac March kers March ket, China, Sales (USD Million), from 2003 to 2010 35
Data table 23: Cardiac March kers March ket, China, Sales (USD Million), from 2010 to 2017 36
Data table 24: Cardiac March kers March ket, India, Sales (USD Million), from 2003 to 2010 37
Data table 25: Cardiac March kers March ket, India, Sales (USD Million), from 2010 to 2017 38
Data table 26: Cardiac March kers March ket, Australia, Sales (USD Million), from 2003 to 2010 39
Data table 27: Cardiac March kers March ket, Australia, Sales (USD Million), from 2010 to 2017 40
Data table 28: Cardiac March kers March ket, Brazil, Sales (USD Million), from 2003 to 2010 41
Data table 29: Cardiac March kers March ket, Brazil, Sales (USD Million), from 2010 to 2017 42
Data table 30: Cardiac March kers March ket, Global, Key Firms Sales (USD Million), 2010 43
Data table 31: F. Hoffman-La-Roche, March keted Products, 2010 46
Data table 32: F. Hoffman-La-Roche, Pipeline Products, 2010 46
Data table 33: Abbott Laboratories, March keted Products 48
Data table 34: Abbott Laboratories, Pipeline Products 48
Data table 35: Siemens Healthcare, March keted Products, 2010 50
Data table 36: Siemens Healthcare, Pipeline Products, 2010 50
Data table 37: Beckman Coulter, Inc, March keted Products 55
Data table 38: Beckman Coulter Inc, Pipeline Products, 2010 56
Data table 39: TROP T Sensitive Rapid Assay, Features and Benefits 58
Data table 40: Cobas c 111 Analyzer, Features and Benefits 58
Data table 41: i-STAT System, Features and Benefits 59
Data table 42: Stratus CS Analyzer, Features and Benefits 59
Data table 43: TriageBNP, Features and Benefits 60
Data table 44: Cardiac March kers March ket, Global, Pipeline Products 61
Data table 45: Cardiac March kers March ket, List of Pipeline Products in Clinical Development 62
Data table 46: Cardiac March kers March ket, List of Pipeline Products in Early Development 63
Data table 47: Cardiac March kers March ket, List of Pipeline Products 64
Data table 48: VASCLIR, Product Status, 2010 65
Data table 49: VASCLIR, Clinical Trials, 2010 65
Data table 50: ARCHITECT MPO ASSAY, Product Status, 2010 66
Data table 51: Architect MPO Assay, Clinical Trials, 2010 66
Data table 52: CADPrint, Product Status, 2010 67
Data table 53: CADPrint, Clinical Trials, 2010 67
Data table 54: PresageAssay ST2, Product Status, 2010 68
Data table 55: PresageAssay ST2, Clinical Trial, 2010 68
Data table 56: Verigene Cardiac Troponin I Assay, Product Status, 2010 69
Data table 57:Verigene Cardiac Troponin I Assay, Clinical Trial, 2010 69
Data table 58:Lab-on-a Film Cardiac Sensor System, Product Status 71

1.2 List of Charts

Chart 1: Cardiovascular Diseases, Pathphysiology 8
Chart 2: Cardiovascular Disease Burden, Global, 2010 9
Chart 3: Cardiac March kers March ket, Global, Sales (USD Million), from 2003 to 2010 11
Chart 4: Cardiac March kers March ket, Global, Sales (USD Million), 2010- 2017 12
Chart 5: Diagnostic Work Flow Diagram for Underlying Personalized Medicine 13
Chart 6: Cardiac March kers March ket, Global, March ket Dynamics 16
Chart 7: Cardiac March kers March ket, the US, Sales (USD Million), from 2003 to 2010 19
Chart 8: Cardiac March kers March ket, the US, Sales (USD Million), from 2010 to 2017 20
Chart 9: Cardiac March kers March ket, Canada, Sales (USD Million), from 2003 to 2010 21
Chart 10: Cardiac March kers March ket, Canada, Sales (USD Million), from 2010 to 2017 22
Chart 11: Cardiac March kers March ket, the UK, Sales (USD Million), from 2003 to 2010 23
Chart 12: Cardiac March kers March ket, the UK, Sales (USD Million), from 2010 to 2017 24
Chart 13: Cardiac March kers March ket, Germany, Sales (USD Million), from 2003 to 2010 25
Chart 14: Cardiac March kers March ket, Germany, Sales (USD Million), from 2010 to 2017 26
Chart 15: Cardiac March kers March ket, France, Sales (USD Million), from 2003 to 2010 27
Chart 16: Cardiac March kers March ket, France, Sales (USD Million), from 2010 to 2017 28
Chart 17: Cardiac March kers March ket, Italy, Sales (USD Million), from 2003 to 2010 29
Chart 18: Cardiac March kers March ket, Italy, Sales (USD Million), from 2010 to 2017 30
Chart 19: Cardiac March kers March ket, Spain, Sales (USD Million), from 2003 to 2010 31
Chart 20: Cardiac March kers March ket, Spain, Sales (USD Million), from 2010 to 2017 32
Chart 21: Cardiac March kers March ket, Japan, Sales (USD Million), from 2003 to 2010 33
Chart 22: Cardiac March kers March ket, Japan, Sales (USD Million), from 2010 to 2017 34
Chart 23: Cardiac March kers March ket, China, Sales (USD Million), from 2003 to 2010 35
Chart 24: Cardiac March kers March ket, China, Sales (USD Million), from 2010 to 2017 36
Chart 25: Cardiac March kers March ket, India, Sales (USD Million), from 2003 to 2010 37
Chart 26: Cardiac March kers March ket, India, Sales (USD Million), from 2010 to 2017 38
Chart 27: Cardiac March kers March ket, Australia, Sales (USD Million), from 2003 to 2010 39
Chart 28: Cardiac March kers March ket, Australia, Sales (USD Million), from 2010 to 2017 40
Chart 29: Cardiac March kers March ket, Brazil, Sales (USD Million), from 2003 to 2010 41
Chart 30: Cardiac March kers March ket, Brazil, Sales (USD Million), from 2010 to 2017 42
Chart 31: Cardiac March kers March ket, Global, Key Market Shares, 2010 43
Chart 32: Cardiac March kers March ket, Competitive Analysis 44
Chart 33: F. Hoffman-La-Roche, SWOT 47
Chart 34: Abbott, SWOT 49
Chart 35: Siemens, SWOT 51
Chart 36: Alere, SWOT 54
Chart 37: Beckman Coulter, SWOT 56
Chart 38: Cardiac March kers March ket, Global, Pipeline Products 61F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Siemens Healthcare
Alere
Beckman Coulter, Inc.

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Shadi

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers

New Frontiers in Automated Microbiology: Global Challenges, Emerging Technologies, Competitive Landscape

New Frontiers in Automated Microbiology: Global Challenges, Emerging Technologies, Competitive Landscape

  • $ 21 100
  • Industry report
  • May 2014
  • by Venture Planning Group

“New Frontiers in Automated Microbiology: Global Challenges, Emerging Technologies, Competitive Landscape” is Venture Planning Group's new seven-country strategic analysis of the major business opportunities ...

Emerging Opportunities in the Global Virology and Bacteriology Testing Market

Emerging Opportunities in the Global Virology and Bacteriology Testing Market

  • $ 21 100
  • Industry report
  • June 2014
  • by Venture Planning Group

“Emerging Opportunities in the Global Virology and Bacteriology Testing Market” is a new seven-country strategic analysis of major business opportunities emerging in the infectious disease testing ...

New Frontiers in Coagulation Testing: Global Challenges, Emerging Technologies, Competitive Landscape

New Frontiers in Coagulation Testing: Global Challenges, Emerging Technologies, Competitive Landscape

  • $ 21 100
  • Industry report
  • May 2014
  • by Venture Planning Group

“New Frontiers in Coagulation Testing: Global Challenges, Emerging Technologies, Competitive Landscape” is Venture Planning Group's new seven-country report designed to help current suppliers and potential ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.